T Cell News and Research

Latest T Cell News and Research

Dupilumab considerably reduced asthma exacerbations in young children, shows VOYAGE trial

Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo, according to research presented at the ATS 2021 International Conference. VOYAGE (NCT02948959) is a recently completed randomized, placebo-controlled double-blind multicenter phase 3 clinical trial, that took place in a number of countries.

20 May 2021

Phase 3 trial: New biologic therapy improves outcomes in adults, adolescents with severe asthma

Results from the NAVIGATOR study of tezepelumab showed that the new biologic therapy significantly reduced exacerbations requiring hospital stays and emergency department (ED) visits for adults and adolescents with severe, uncontrolled asthma, according to research presented at the ATS 2021 International Conference.

20 May 2021

Blocking ABCB10 protein in liver cells protects against high blood sugar, fatty liver disease

A new multi-institution study led by a team of researchers at the David Geffen School of Medicine demonstrated that blocking a protein called ABCB10 in liver cells protects against high blood sugar and fatty liver disease in obese mice.

20 May 2021

Does cross-immunity exist between SARS-CoV-2 B.1.1.28 and P.1 variants?

A team of researchers recently cross-tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies to assess their neutralization activity against different variants. The team recently released their findings as a preprint on the medRxiv* server.

20 May 2021

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

A new study has been published in Small, which has combined in silico and in vitro analysis to examine if graphene oxide (GO) sheets have an inhibitory effect against SARS‐CoV‐2 surface proteins.

20 May 2021

Are COVID-19-related complications in children explained by abnormal immune responses?

A common theme in reports on COVID-19 around the world has been the large number of children who have not been infected or shown signs of disease. However, though the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes less acute infection in this age group, it is associated with a severe immune-mediated multisystemic illness called multisystem inflammatory syndrome in children (MIS-C).

20 May 2021

Extensive cancer research data to be presented at the 2021 ASCO Annual Meeting

Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and health outcomes analyses and a designated Comprehensive Cancer Center by the National Cancer Institute, together with RWJBarnabas Health, today announced that data from its cancer clinical research program will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8.

20 May 2021

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

An interim report on a phase 2 clinical trial indicates both the safety and efficacy of a plant-produced virus-like particle vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine candidate has shown an acceptable safety profile and high potency in inducing humoral and cellular immune responses in adults (18 – 64 years) and elderly (65 years and above) individuals. The report is currently available on the medRxiv* preprint server.

20 May 2021

Study could serve as guidepost for developing new therapies for Alzheimer's disease

In a major breakthrough, researchers at Massachusetts General Hospital (MGH) have discovered how amyloid beta--the neurotoxin believed to be at the root of Alzheimer's disease (AD)--forms in axons and related structures that connect neurons in the brain, where it causes the most damage.

20 May 2021

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Researchers in the UK have developed a protein-based subunit vaccine directed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as an alternative to the mRNA-based vaccines currently approved for protecting against coronavirus disease 2019 (COVID-19).

20 May 2021

Antithrombotic endothelial dysfunction is prevented by Tie2 activation in severe COVID-19

Researchers from the US recently assessed if severe COVID-19 is linked to procoagulant dysfunction of the endothelium and changes in the Tie2-angiopoietin axis. They assessed circulating endothelial markers in a study cohort of 98 patients with mild, moderate, or severe COVID-19. This study is published on the medRxiv* preprint server.

19 May 2021

Potential immunotherapy may improve cognitive and behavioral functions after stroke

Specialized immune cells that accumulate in the brain in the days and weeks after a stroke promote neural functions in mice, pointing to a potential immunotherapy that may boost recovery after the acute injury is over, University of Pittsburgh School of Medicine neurologists found.

19 May 2021

T Cell News and Research

Latest T Cell News and Research

Dupilumab considerably reduced asthma exacerbations in young children, shows VOYAGE trial

Phase 3 trial: New biologic therapy improves outcomes in adults, adolescents with severe asthma

Blocking ABCB10 protein in liver cells protects against high blood sugar, fatty liver disease

Does cross-immunity exist between SARS-CoV-2 B.1.1.28 and P.1 variants?

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

Are COVID-19-related complications in children explained by abnormal immune responses?

Extensive cancer research data to be presented at the 2021 ASCO Annual Meeting

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

Study could serve as guidepost for developing new therapies for Alzheimer's disease

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Antithrombotic endothelial dysfunction is prevented by Tie2 activation in severe COVID-19

Potential immunotherapy may improve cognitive and behavioral functions after stroke

Researchers use base editing to sustainably lower high LDL cholesterol levels

Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

Spike antibodies after vaccination with Pfizer and Oxford vaccines

To the bat cave: In search of covid’s origins, scientists reignite polarizing debate on Wuhan ‘lab leak’

Toll-like receptor 2 (TLR2) detects the SARS-CoV-2 envelope protein and generates inflammatory cytokines

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

Immunology eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in